10-K: Aligos Therapeutics Reports Full Year 2023 Results, Highlights Progress in MASH and Viral Disease Programs

Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its 10-K filing for the fiscal year ended December 31, 2023, detailing progress in its MASH and viral disease programs and financial results.

Summary

• Aligos Therapeutics is focused on developing treatments for liver diseases and viral infections, including MASH, chronic hepatitis B (CHB), and coronaviruses.
• The company's lead MASH drug candidate, ALG055009, is a THR agonist that has completed Phase 1 trials and is entering a Phase 2a proof-of-concept study.
• For CHB, ALG000184, a CAM-E, has shown promising antiviral activity in Phase 1b trials, with ongoing studies evaluating longer-term dosing.
• Aligos is also developing ALG125755, an siRNA for CHB, and small molecule PD-1/PD-L1 inhibitors to boost immune responses.
• In the coronavirus space, ALG097558, a protease inhibitor, has demonstrated potent pan-coronavirus activity and is in Phase 1 trials.
• The company anticipates sharing topline data from the ALG-097558 Phase 1 study in the second quarter of 2024.
• Aligos received approximately $11.0 million in NIH funding to support clinical and nonclinical studies for its coronavirus program.
• The company reported a net loss of $87.7 million for 2023 and $96.0 million for 2022.
• As of December 31, 2023, Aligos had cash, cash equivalents, and investments of $135.7 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in the clinical development of several drug candidates and some financial support from NIH, the company is still in the early stages of development, has incurred significant losses, and faces substantial risks and competition. The company's stock price may be volatile and the company may be delisted from Nasdaq. The sentiment is neutral to slightly negative.

Positives

• ALG055009 has shown greater beta selectivity and higher potency for the THRbeta receptor compared to other THR agonists in development.
• ALG000184 has demonstrated potentially best-in-class antiviral activity in CHB patients.
• ALG097558 is at least 6-fold more potent than nirmatrelvir in cell-based assays against SARS-CoV-2 variants.
• The company has a strong management team with a track record of success in drug discovery and development.
• Aligos has a robust pipeline of multiple novel drug candidates.

Negatives

• The company has incurred significant losses since inception and expects to incur losses for at least the next several years.
• Aligos has never generated revenue from product sales and may never be profitable.
• The company will require substantial additional financing to achieve its goals.
• The company is early in its development efforts and its business is dependent on the successful development of its drug candidates.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company's stock may be delisted from Nasdaq if it fails to comply with continued listing requirements.

Risks

• The company's drug candidates may cause undesirable side effects or have other properties that could delay or halt their clinical development.
• Aligos depends on collaborations with third parties, and if these collaborations are not successful, the company may not be able to capitalize on the market potential of its drug candidates.
• The company faces significant competition, and if competitors develop more effective, safer, or less expensive products, Aligos' commercial opportunities will be negatively impacted.
• If Aligos is unable to obtain, maintain, protect, and enforce sufficient patent and other intellectual property protection, competitors could develop and commercialize similar products.
• Third parties may initiate legal proceedings alleging that Aligos is infringing on their intellectual property rights.
• The company is highly dependent on key personnel, and if it is not successful in attracting, motivating, and retaining qualified personnel, it may not be able to successfully implement its business strategy.

Future Outlook

Aligos expects to continue to incur significant expenses and increasing operating losses over at least the next several years. The company anticipates sharing topline data from the ALG-097558 Phase 1 study in the second quarter of 2024 and initiating a Phase 2a proof of concept study for ALG055009 in the second quarter of 2024, with topline safety and 12 week MRI-PDFF data expected in the fourth quarter of 2024.

Management Comments

• The management team consists of a group of highly collaborative, culturally diverse executives with decades of drug discovery and development experience.
• The management team has been collectively involved in the discovery and/or development of a number of drugs that have been successfully commercialized.

Industry Context

The document highlights Aligos' focus on MASH and viral diseases, which are areas of significant unmet medical need and are attracting substantial investment and research efforts from both large pharmaceutical companies and smaller biotechnology firms. The company's approach of combining multiple mechanisms of action is consistent with the industry trend towards combination therapies for complex diseases.

Comparison to Industry Standards

• Aligos' THR agonist, ALG055009, is compared to resmetirom and VK-2809, two other THR agonists in clinical development, with Aligos claiming greater potency and selectivity.
• Aligos' CAM-E, ALG000184, is compared to other CAM-Es in clinical trials, with Aligos claiming potentially best-in-class antiviral activity.
• Aligos' pan-coronavirus protease inhibitor, ALG097558, is compared to nirmatrelvir and other PIs in clinical development, with Aligos claiming greater potency and broad pan-coronavirus activity.
• The document notes that multiple siRNAs have demonstrated significant reductions in HBsAg levels in clinical trials, and Aligos' siRNA, ALG125755, is compared to VIR-2218 based on a reported AAV-HBV experiment, though not a head-to-head study.

Management Changes

Legal Proceedings

• The company was involved in a legal proceeding with Janssen Biopharma, LLC, which was resolved through a settlement agreement in October 2023.

Stakeholder Impact

• Shareholders face the risk of stock price volatility and potential dilution from future capital raises.
• Employees may experience job insecurity due to the company's financial situation and dependence on key personnel.
• Customers (potential patients) may benefit from the development of new treatments for MASH, CHB, and coronaviruses.
• Suppliers and creditors face the risk of non-payment if the company's financial situation deteriorates.
• Collaborators face the risk of unsuccessful partnerships and potential termination of agreements.

Next Steps

• Initiate a Phase 2a proof of concept study (HERALD) for ALG-055009 in the second quarter of 2024.
• Continue dosing of HBeAg positive/negative subjects with ALG000184 + ETV in ongoing cohorts throughout 2024.
• Share topline data from the ALG-097558 Phase 1 study at a scientific conference in the second quarter of 2024.
• Conduct clinical pharmacology studies for ALG-097558 in the second half of 2024 through the end of 2025 as part of the NIAID contract.
• Seek additional external funding to support future studies (e.g., Phase 2) for ALG-097558.

Key Dates

Keywords

MASH, NASH, chronic hepatitis B, CHB, coronavirus, SARS-CoV-2, THR agonist, CAM-E, siRNA, protease inhibitor, clinical trials, drug development, biopharmaceutical, oligonucleotide, small molecule